Icatibant Fresenius (Icatibant Acetate)

Icatibant Acetate blocks the bradykinin B2 receptor, preventing bradykinin from causing vasodilation and increased vascular permeability. This inhibition stops the cascade that leads to the swelling seen in hereditary angioedema.

The dose and administration schedule are determined by the prescribing healthcare professional based on the patient’s condition and clinical guidelines. Patients should follow the prescriber’s instructions exactly.

Safety in pregnancy and lactation has not been established. The drug should be used only if the potential benefit justifies the potential risk to the fetus or infant, and under close medical supervision.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Icatibant is a bradykinin B2 receptor antagonist, whereas other options such as C1‑inhibitor concentrates replace the deficient protein. Icatibant provides a rapid, targeted approach to block bradykinin‑mediated swelling, while C1‑inhibitor therapy works upstream by restoring the regulatory protein.

The product must be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use to maintain stability.

Icatibant Fresenius is given as a subcutaneous injection, typically into the abdomen or thigh. The injection is performed by a trained healthcare professional or the patient after proper instruction.

Serious risks include anaphylaxis, severe hypersensitivity reactions, and rare cases of systemic angioedema unrelated to hereditary disease. Patients should be monitored for any signs of allergic reaction immediately after injection.

Individuals with known hypersensitivity to icatibant acetate or any of its excipients should avoid the product. It is also contraindicated in patients who have experienced severe allergic reactions to other bradykinin B2 receptor antagonists.